Form 4: Clorox Director Boosts Stake via DSU Awards

A.D. David MacKay, a Director at Clorox, increased his beneficial ownership of the company's stock through deferred stock unit acquisitions and an annual award.

Summary

• Director A.D. David MacKay acquired additional Deferred Stock Units (DSUs) in The Clorox Co. (CLX) on multiple dates in 2025.
• Acquisitions included 74.9914 DSUs on February 14, 2025; 82.9936 DSUs on May 9, 2025; 97.043 DSUs on August 29, 2025; and 109.0592 DSUs on November 6, 2025, all through dividend reinvestment under the Independent Directors' Deferred Compensation Plan.
• An annual award of 1,637.8577 DSUs was received on December 31, 2025, pursuant to the 2005 Stock Incentive Plan.
• These Deferred Stock Units convert 1-for-1 into Common Stock and will be settled upon MacKay's retirement or other termination of service as a Director.
• Following these transactions, MacKay beneficially owns a total of 11,094.3468 Deferred Stock Units.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The filing indicates a director's increased beneficial ownership through routine compensation and dividend reinvestment, which is generally a positive signal of alignment with shareholder interests, though not indicative of new strategic developments.

Positives

• Director MacKay increased his beneficial ownership, indicating continued confidence in the company's future performance.
• The acquisitions include dividend reinvestment, demonstrating a long-term investment strategy and commitment to the company.
• Transactions were made pursuant to a Rule 10b5-1 plan, suggesting pre-planned, non-discretionary acquisitions that align with good corporate governance.

Future Outlook

The Deferred Stock Units will be settled 100% in Clorox common stock in connection with the reporting person's retirement or other termination of service as a Director, indicating a future conversion of these units into common stock.

Industry Context

This Form 4 filing reflects routine insider compensation and dividend reinvestment activities, common across many publicly traded companies, particularly for long-serving directors. It does not indicate any specific industry-wide trends beyond standard corporate governance practices for executive and director compensation.

Comparison to Industry Standards

• The acquisition of Deferred Stock Units through dividend reinvestment and annual awards is a standard practice for director compensation in many large consumer goods companies, similar to peers like Procter & Gamble (PG) or Kimberly-Clark (KMB), where directors often receive equity-based compensation to align their interests with shareholders.
• The use of a Rule 10b5-1 plan for these transactions is also a common corporate governance best practice to mitigate concerns about insider trading.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to higher equity ownership.

Next Steps

• Settlement of Deferred Stock Units into Clorox common stock upon the reporting person's retirement or termination of service as a Director.

Key Dates

Recommendation

This Form 4 filing details routine, pre-scheduled acquisitions of deferred stock units by a director as part of their compensation and dividend reinvestment plan. While an increase in insider ownership is generally a positive signal of confidence, these transactions are not discretionary open-market purchases and do not provide new fundamental information to warrant a change in investment recommendation. The filing reinforces a 'hold' stance, as it confirms ongoing director alignment without introducing new catalysts for significant price movement.

Keywords

Clorox, CLX, Insider Transaction, Form 4, Deferred Stock Units, Director Compensation, Dividend Reinvestment, Beneficial Ownership, Stock Incentive Plan